Marion Bouchecareilh, CR CNRS team 8, is organizing an information and exchange day for patients with Alpha 1-Antitrypsin deficiency concerning siRNA treatments for the liver damage associated with this deficiency, on Saturday August 31, 2024 in Bordeaux (Campus Bordeaux Pey-Berland). The aim of this event, which will be attended by a number of French experts, is to present and explain to patients the mode of action of siRNA treatments, the various clinical trials currently underway and their modalities, and feedback on this type of treatment for other pathologies. The aim of this meeting is to provide an opportunity for exchange and sharing between patients, patient associations and the various players involved in understanding and combating the symptoms associated with this deficiency. Program available at this link Hybrid format. Free but mandatory registration before August 15 at this link  Interview with Dr Marion Bouchecareilh for FilFoie, partner of this event, available at this link.

Dr Marion Bouchecareilh presents the rare disease she is studying: Alpha 1-Antitrypsin deficiency, and the ongoing Phase 3 clinical trial involving siRNA treatment of liver damage associated with this deficiency. She also takes advantage of this interview to talk about the projects she is developing concerning primary hepatopathies and cancers of the liver associated with Alpha 1-Antitrypsin deficiency. Dr Bouchecareilh is leading the latter project in partnership with Dr Samuel Amintas, MCU-PH also in BRIC team 8.